LT3127544T - Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis - Google Patents

Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis

Info

Publication number
LT3127544T
LT3127544T LTEPPCT/JP2015/060635T LT15773963T LT3127544T LT 3127544 T LT3127544 T LT 3127544T LT 15773963 T LT15773963 T LT 15773963T LT 3127544 T LT3127544 T LT 3127544T
Authority
LT
Lithuania
Prior art keywords
antificant
anticonental
administrative
efficient
product containing
Prior art date
Application number
LTEPPCT/JP2015/060635T
Other languages
English (en)
Inventor
Hiroyuki Okabe
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of LT3127544T publication Critical patent/LT3127544T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/JP2015/060635T 2014-04-04 2015-04-03 Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis LT3127544T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014078242 2014-04-04
JP2015024802 2015-02-10
PCT/JP2015/060635 WO2015152407A1 (ja) 2014-04-04 2015-04-03 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤

Publications (1)

Publication Number Publication Date
LT3127544T true LT3127544T (lt) 2021-11-25

Family

ID=54240714

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/JP2015/060635T LT3127544T (lt) 2014-04-04 2015-04-03 Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis

Country Status (20)

Country Link
US (1) US10092589B2 (lt)
EP (1) EP3127544B1 (lt)
JP (1) JP6458007B2 (lt)
KR (1) KR101964169B1 (lt)
AU (1) AU2015242786B2 (lt)
CY (1) CY1124709T1 (lt)
DK (1) DK3127544T3 (lt)
ES (1) ES2896051T3 (lt)
HR (1) HRP20211709T8 (lt)
HU (1) HUE056497T2 (lt)
LT (1) LT3127544T (lt)
NZ (1) NZ725067A (lt)
PL (1) PL3127544T3 (lt)
PT (1) PT3127544T (lt)
RS (1) RS62560B1 (lt)
RU (1) RU2678103C2 (lt)
SI (1) SI3127544T1 (lt)
SM (1) SMT202100639T1 (lt)
UA (1) UA121862C2 (lt)
WO (1) WO2015152407A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167256A1 (en) * 2017-03-17 2018-09-20 Les Laboratoires Servier Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
CN118059211B (zh) * 2024-01-09 2024-09-03 珠海市藤栢医药有限公司 一种含多肽的药物组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
CZ288406B6 (en) * 1998-05-27 2001-06-13 Lachema Np Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN105147713A (zh) * 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
NZ597339A (en) * 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CA2805874A1 (en) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2012332424A1 (en) * 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents

Also Published As

Publication number Publication date
HUE056497T2 (hu) 2022-02-28
NZ725067A (en) 2019-01-25
HRP20211709T1 (hr) 2022-02-04
RS62560B1 (sr) 2021-12-31
EP3127544A1 (en) 2017-02-08
AU2015242786B2 (en) 2018-11-22
RU2678103C2 (ru) 2019-01-23
RU2016143220A3 (lt) 2018-08-24
JPWO2015152407A1 (ja) 2017-04-13
EP3127544A4 (en) 2017-12-13
DK3127544T3 (da) 2021-11-08
UA121862C2 (uk) 2020-08-10
EP3127544B1 (en) 2021-09-15
AU2015242786A1 (en) 2016-11-10
WO2015152407A1 (ja) 2015-10-08
SI3127544T1 (sl) 2021-12-31
HRP20211709T8 (hr) 2022-03-04
RU2016143220A (ru) 2018-05-07
ES2896051T3 (es) 2022-02-23
KR20160140839A (ko) 2016-12-07
PL3127544T3 (pl) 2022-01-03
CY1124709T1 (el) 2022-07-22
SMT202100639T1 (it) 2022-01-10
PT3127544T (pt) 2021-11-08
US10092589B2 (en) 2018-10-09
KR101964169B1 (ko) 2019-04-01
US20170216339A1 (en) 2017-08-03
JP6458007B2 (ja) 2019-01-23

Similar Documents

Publication Publication Date Title
LT3099717T (lt) Antikūno molekulės tim-3-čiam ir jų panaudojimas
SG11201702299SA (en) Pharmaceutical product
HUE052280T2 (hu) Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
HUE045234T2 (hu) Gyógyszeradagolás tanulása
DK3160978T3 (da) Gemcitabin-prodrugs
BR112016026078A2 (pt) Produto absorvente
IL252574A0 (en) Oral care product
LT3215118T (lt) Vaisto ir medicininės priemonės komplektas, kurio sudėtyje yra kvinagolidas
HUE050697T2 (hu) Gyógyszerkészítmények és ezek alkalmazása
LT3127544T (lt) Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis
FR3021219B1 (fr) Oligo-porphyranes, procede et medicament
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
HUE044257T2 (hu) Méh termékeket tartalmazó készítmények
CN303248952S (zh) 使用外观设计的产品名称
UA33468S (uk) Кулінарний виріб
UA33334S (uk) Кулінарний виріб
UA28425S (uk) Кулінарний виріб
UA29044S (uk) Хлібобулочний виріб
FR3019990B3 (fr) Produit medical
UA29829S (uk) Пляшка для лікарських засобів
UA30739S (uk) Хлібобулочний виріб
UA27515S (uk) Пляшка для лікарських засобів
UA27616S (uk) Пляшка для лікарських засобів
TH1401006892B (th) ผลิตภัณฑ์นาโนเคอร์คูมินที่ไวต่ออุณหภูมิ
TH1501007914B (th) ผลิตภัณฑ์สวมใส่ดึงสวมชนิดใช้แล้วทิ้ง